|
|
|
| Clinical Observation of Wuzhi Capsule Combined with Tacrolimus in the treatment of Hepatitis B Virus-associated Nephritis |
| ZHAO Rui, QI Li |
| Weifang Medical College, Shandong Weifang 261000, China |
|
|
|
|
Abstract Objective: To observe the effect of Wuzhi capsule combined with tacrolimus on hepatitis B virus-associated nephritis. Methods: The prospective randomized controlled trial was used to observe the HBV-GN patients who visited the Affiliated Hospital of Weifang Medical College from July 2015 to August 2018. 62 patients meeting the inclusion criteria were divided into treatment group (33 cases) and control group (29 cases). Patients in the treatment group were treated with Wuzhi capsule combined with tacrolimus and entecavir for 12 months, while those in the control group were treated with entecavir alone for 12 months.Alt, AST, ALB, UTP (24h), SCR, HBV DNA titer were analyzed by statistical method. The clinical efficacy of Wuzhi capsule combined with tacrolimus and entecavir in the treatment of hepatitis B-related nephritis was studied. Results: The total remission rate of Wuzhi capsule combined with tacrolimus and entecavir was 87.88% after 12 months, compared with 62.07% in entecavir group (P < 0.05). The serum levels of ALT, AST, ALB, and uTP (24h) in the treatment group were significantly better than those in the control group at 6 and 12 months (P<0.05). After 12 months of treatment, HBV DNA titer decreased in the treatment group, and the difference was statistically significant (P<0.05). The Scr value was no significant change after treatment, there was no difference (P>0.05). Conclusion: Wuzhi capsule combined with tacrolimus and entecavir can effectively induce the remission of HBV-GN, better protect the function of liver and kidney, and have good safety, which is worthy of clinical reference.
|
|
|
|
|
|
[1] 张国山,王芳,安爽,等.乙型肝炎病毒相关性肾炎的研究进展[J].中国老年学杂志,2015,30(4):1130~1133.
[2] DuY,ZhangS,HuM,et al.Association between hepatitis B virus infection and chronic kidney disease: a cross-sectional study from 3 million population aged 20 to 49 years in rural China[J].Medicine (Baltimore), 2019, 98(5):142~62.
[3] Wang WN,Wu MY,Ma FZ,et al.Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis[J]. Clinical Nephrology, 2016,85(1):21~29.
[4] 王硕, 黄建萍,都娟,等.五酯胶囊在服用他克莫司的肾脏疾病患儿中的作用及成本效果分析[J].中国医刊,2016(3):115~118.
[5] 蔡卫华,张琳,张劢,等.复方五仁醇胶囊、五酯胶囊对他克莫司血药浓度影响及肝损伤保护作用的比较[J].中成药,2019(6):1431~1433.
[6] 唐亚,王俭勤.乙型肝炎病毒相关性肾小球肾炎的发病机制[J].临床肾脏病杂志,2018,18(1):54~56.
[7] 高志芳,陈坚华,潘燕芳,等.恩替卡韦对改善乙型肝炎病毒相关性肾炎肾功能的临床观察[J].中国实用医药,2018(3):79~80.
[8] 万静芳.他克莫司治疗乙型肝炎病毒相关性膜性肾病的随机对照临床试验[J].中华肾脏病杂志,2015,31(1):1~6.
[9] 侯朝阳.五酯胶囊联合复方益肝灵片对脂肪肝患者肝功能的保护作用[J].中国药业,2016,25(4):65~67.
[10] 杨敏,刘云启,魏传梅,等.五酯胶囊对CYP3A5基因表达型特发性膜性肾病他克莫司药代动力学影响的初步探索[J].国际泌尿系统杂志,2016,36(2):223~228.
[11] Wang K,Qu Q S,Zhang Y X,et al. Effects of Wuzhi capsule on blood concentration of tacrolimus after renal transplantation[J].Biol Regul Homeost Agents,2015,30(1):155~159. |
|
|
|
2020, Vol. 26 
